BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BC Extra | Mar 9, 2018
Company News

Coherus gains on plans to resubmit BLA for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) rose $2.75 (30%) to $11.85 on Friday after announcing in its earnings that it will resubmit a BLA for CHS-1701, with plans to launch the product in the U.S. next half....
BC Week In Review | Jul 7, 2017
Clinical News

Daiichi ends Japanese development of Coherus' Enbrel biosimilar

Daiichi Sankyo Co. Ltd. (Tokyo:4568) discontinued development in Japan of CHS-0214 (BAX 2200), a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), to treat rheumatoid arthritis. Coherus BioSciences Inc. (NASDAQ:CHRS) said it regained territorial rights...
BC Extra | Jul 5, 2017
Company News

Daiichi ends development of Coherus' biosimilar of Enbrel

Coherus Biosciences Inc. (NASDAQ:CHRS) slipped $0.25 to $14.40 on Wednesday after partner Daiichi Sankyo Co. Ltd. (Tokyo:4568) discontinued development in Japan of CHS-0214 , a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), to treat rheumatoid...
BC Innovations | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc. ’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research...
BC Week In Review | Dec 21, 2016
Clinical News

Lifmior regulatory update

EMA’s CHMP recommended approval of Pfizer’s Lifmior etanercept, a product identical to Enbrel , to treat rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and pediatric plaque psoriasis. Pfizer has rights to...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BC Week In Review | Nov 18, 2016
Company News

LG Life Sciences, LG Chem deal

In September, LG Corp. (KSE:003550, Seoul, South Korea) affiliates LG Life Sciences and LG Chem said they would merge in a stock deal, with the latter remaining as the surviving entity. The deal is expected...
BioCentury | Oct 3, 2016
Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BC Week In Review | Sep 19, 2016
Clinical News

Brenzys biosimilar etanercept regulatory update

Samsung Bioepis Co. Ltd. and Merck said Canada approved Brenzys etanercept, a biosimilar of autoimmune drug Enbrel etanercept, to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Merck will commercialize the biosimilar in Canada. The...
Items per page:
1 - 10 of 164